Tisotumab Vedotin, an anti-TF mAb (TF-011) drug conjugate has shown promising anti-tumour activity in clinical trials and is currently FDA-approved for recurrent and metastatic cervical cancer [43, 44]. This evidence concerns the gene TF and neoplasm.